fbpx
Size of letters 1x
Site color
Image
Additionally
Line height
Letter spacing
Font
Embedded items (videos, maps, etc.)
 

EBA discusses the Procedure for Maintaining the State Register of Clinical Trials with the Ministry of Health and the State Expert Centre

16/ 11/ 2026
  On 11 November, the European Business Association’s Clinical Trials Subcommittee held a working meeting with the Ministry of Health of Ukraine and the State Expert Centre of the Ministry of Health of Ukraine. The participants discussed the EBA’s proposals to the draft Ministry of Health Order “Certain Issues Related to Maintaining the State Register of Clinical Trials (Trials) of Medicinal Products”, submitted as part of the public consultation, as well as the revised version of the document prepared by the Ministry. During the meeting, Ministry representatives presented the results of their review of the Subcommittee’s proposals. A number of recommendations from the business community have already been incorporated into the revised draft, including those concerning the display of current and historical information on clinical trials, the use of Latin characters for names and codes, and the protection of information designated as confidential by the sponsor. Particular attention was paid to ensuring that the future Register is accessible and user-friendly for patients, physicians and trial sponsors. The revised draft provides for the possibility to search, view, copy and save information from the Register, as well as to see the dates when information was entered and last updated. The Ministry confirmed that the Register will be free of charge and that viewing publicly available information will not require electronic identification. The draft also provides for the publication of summaries of clinical trial results for the general public. At the same time, the Association’s Subcommittee representatives reiterated the importance of enabling users to generate and download reports based on Register data, which would facilitate the effective use of information by all user groups. Several of the Subcommittee’s proposals, including the possibility of generating and downloading reports based on Register data and displaying up-to-date information on patient recruitment, were discussed further. In the experts’ view, it is important for patients considering participation in clinical trials to be able to find out whether recruitment is ongoing for a particular trial and at which research sites. The meeting participants acknowledged the potential value of such functionality for patients, researchers and trial sponsors. At the same time, its practical implementation requires further consideration, taking into account the Register’s functional capabilities and development prospects. The participants also reviewed the scope of information on medicinal products and related materials to be included in the Register. The EBA emphasised the importance of including only the information that is necessary and avoiding excessive administrative burdens. In particular, the discussion addressed whether information on concomitant therapy should be mandatory. Given that this data may be used during customs clearance of materials for clinical trials, the relevant approaches require further consideration. Following the meeting, Ministry representatives informed the participants that the revised draft would be published again for public consultation. The parties agreed to continue working together on the outstanding issues. Proposals requiring additional analysis or technical improvements to the Register’s functionality may be discussed further at subsequent stages of its development. The EBA’s Clinical Trials Subcommittee thanks the representatives of the Ministry of Health and the State Expert Centre for the professional and constructive dialogue and their openness to proposals from the business community. We will continue working to improve the regulatory framework for clinical trials in Ukraine.

On 11 November, the European Business Association’s Clinical Trials Subcommittee held a working meeting with the Ministry of Health of Ukraine and the State Expert Centre of the Ministry of Health of Ukraine. The participants discussed the EBA’s proposals to the draft Ministry of Health Order “Certain Issues Related to Maintaining the State Register of Clinical Trials (Trials) of Medicinal Products”, submitted as part of the public consultation, as well as the revised version of the document prepared by the Ministry.

During the meeting, Ministry representatives presented the results of their review of the Subcommittee’s proposals. A number of recommendations from the business community have already been incorporated into the revised draft, including those concerning the display of current and historical information on clinical trials, the use of Latin characters for names and codes, and the protection of information designated as confidential by the sponsor.

Particular attention was paid to ensuring that the future Register is accessible and user-friendly for patients, physicians and trial sponsors. The revised draft provides for the possibility to search, view, copy and save information from the Register, as well as to see the dates when information was entered and last updated. The Ministry confirmed that the Register will be free of charge and that viewing publicly available information will not require electronic identification. The draft also provides for the publication of summaries of clinical trial results for the general public. At the same time, the Association’s Subcommittee representatives reiterated the importance of enabling users to generate and download reports based on Register data, which would facilitate the effective use of information by all user groups.

Several of the Subcommittee’s proposals, including the possibility of generating and downloading reports based on Register data and displaying up-to-date information on patient recruitment, were discussed further. In the experts’ view, it is important for patients considering participation in clinical trials to be able to find out whether recruitment is ongoing for a particular trial and at which research sites. The meeting participants acknowledged the potential value of such functionality for patients, researchers and trial sponsors. At the same time, its practical implementation requires further consideration, taking into account the Register’s functional capabilities and development prospects.

The participants also reviewed the scope of information on medicinal products and related materials to be included in the Register. The EBA emphasised the importance of including only the information that is necessary and avoiding excessive administrative burdens. In particular, the discussion addressed whether information on concomitant therapy should be mandatory. Given that this data may be used during customs clearance of materials for clinical trials, the relevant approaches require further consideration.

Following the meeting, Ministry representatives informed the participants that the revised draft would be published again for public consultation. The parties agreed to continue working together on the outstanding issues. Proposals requiring additional analysis or technical improvements to the Register’s functionality may be discussed further at subsequent stages of its development.

The EBA’s Clinical Trials Subcommittee thanks the representatives of the Ministry of Health and the State Expert Centre for the professional and constructive dialogue and their openness to proposals from the business community. We will continue working to improve the regulatory framework for clinical trials in Ukraine.

If you have found a spelling error, please, notify us by selecting that text and pressing Ctrl+Enter.

Start
in the Telegram bot
Read articles. Share in social networks
Nationwide Minute of Silence
01:00
09:00
Nationwide Minute of Silence
Let us honor the memory of all those who lost their lives in russia’s war against Ukraine
00:43

Spelling error report

The following text will be sent to our editors: